PBM DIR Fees Costing Medicare and Beneficiaries: Investigative White Paper on Background, Cost Impact, and Legal Issues

January 2017 New White Paper Reveals How Pharmacy Benefits Managers Use DIR Fees for Corporate Profit at the Expense of Patient Care. Read Full Study Here >>

2016 Practice Impact Report

,

October 2016
The 2016 Community Oncology Practice Impact Report tracks the changing landscape of cancer care in the United States.
Read Full Study Here >>

New White Paper: PBM’s Attack on Physician Dispensing and Impact on Patient Care

,

August 2016
Physician dispensing has been a critical part of the American healthcare system for decades, and dispensing physician practices have...
Read Full Study Here >>

Issue Brief: In-House and Specialty Pharmacies

August 2016
Within a community oncology practice, the in-house pharmacy provides oral and infused drugs, prescribed by the practice physicians...
Read Full Study Here >>

Bad Medicine: Oncologists Review the Evidence

May 2016
A recently released report from Memorial Sloan-Kettering Cancer Center’s (MSK) EvidenceDriven Drug Pricing Project (EDPP) ...
Read Full Study Here >>

Fact-Checking the MSK Review of Congressional Concerns Regarding Medicare Part B

May 2016
Researchers from the MSK Evidence Driven Drug Pricing Project have now released two reports...
Read Full Study Here >>

Cost Drivers of Cancer Care

April 2016
Nearly 14.5 million Americans with a history of cancer were alive in 20141 and that number is projected to increase to 18.1 million in 2020.
Read Full Study Here >>

340B Growth & the Impact on the Oncology Marketplace: Update

December 2015
Since May 2015, government agencies have issued a number of significant reports and guidance notices...
Read Full Study Here>>